High‐risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification. Issue 10 (19th June 2020)

• Record Type: Journal Article
• Authors: Smith, Scott C.; Althof, Pamela A.; Dave, Bhavana J.; Sanmann, Jennifer N.
• Is Part Of: Genes, chromosomes & cancer. Volume 59:Issue 10(2020)
• Page Start: 569
• Page End: 574
• Publication Date: 2020-06-19
• Subjects: high‐risk cytogenetics -- IGH deletion -- IGH rearrangement -- multiple myeloma -- plasma cell dyscrasia; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22874
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Multiple myeloma is a clonal malignancy of plasma cells in the bone marrow. Risk stratification is partly based on cytogenetic findings that include abnormalities of the IGH locus as determined by fluorescence in situ hybridization (FISH), such as rearrangements that result in either standard‐risk or high‐risk gene fusions. IGH deletions have been evaluated as a group in multiple myeloma patients with respect to cumulative outcomes but have provided limited guidance. Whether these deletions have the potential to result in gene fusions and thus further stratify patients is unknown. We identified 229 IGH deletions in patients referred for plasma cell dyscrasia genetic testing over 5.5 years. Follow‐up was conducted on 208 of the deletions with dual fusion FISH probes for standard‐risk ( IGH ‐ CCND1 ) and high‐risk IGH gene fusions ( IGH ‐ FGFR3, IGH ‐ MAF, IGH ‐ MAFB ). Of all deletions identified with follow‐up, 44 (21%) resulted in a gene fusion as detected by FISH, 15 (7%) of which were fusion partners associated with high‐risk multiple myeloma. All fusion‐positive 3′‐ IGH deletions (6 fusions) resulted in high‐risk IGH ‐ FGFR3 fusions. Of the 15 high‐risk fusion‐positive cases, eight were without other high‐risk cytogenetic findings. This study is the first to evaluate the presence of IGH gene fusions upon identification of IGH deletions and to characterize the deletion locus. Importantly, these findings indicate that follow‐up FISH studies with dual fusion probes should be standard of care when IGH deletions are identified in multiple myeloma.